RS Virus (Maternal and Child Immunity Vaccine) Vaccination (Routine Vaccination)

About the Routine Vaccination of RS Virus (Maternal and Child Immunity Vaccine) Vaccination

The Ministry of Health, Labor and Welfare is advancing discussions on making the RS virus (maternal antibody vaccine) vaccination part of the routine vaccination program.
Vaccinations administered on or after April 1, 2026, are expected to be included in the routine vaccination program.

Details will be updated as needed.

 

Back to the top of this page

What is RS Virus Infection?

An acute respiratory infection caused by RS virus, which is a common infection among infants and young children.

RS virus can infect repeatedly regardless of age, but the initial infection is said to be more likely to become severe. In particular, if infected within 6 months after birth, it can become severe, causing bronchiolitis or pneumonia. It is said that more than 50% of infants and young children are infected at least once by the age of 1, and almost 100% by the age of 2.

Back to the top of this page

About the Effectiveness of the Vaccine

By receiving the RSV vaccine during pregnancy, antibodies are transferred to the baby through the placenta, which is expected to prevent severe RSV infection until the baby is 6 months old.

Back to the top of this page

Routine Vaccination Eligible Persons (Planned)

For vaccination dates on or after April 1, 2026, pregnant women who have a Certificate of Residence in Inagi City at the time of vaccination and are between 28 weeks 0 days and 36 weeks 6 days of pregnancy

Back to the top of this page

Number of Vaccinations (Planned)

You can receive one vaccination per pregnancy

 

Back to the top of this page

Other Information Regarding Vaccination

We will inform you on the website as soon as the details are available.

Back to the top of this page

Reference Information

• RS Virus Infection (Ministry of Health, Labor and Welfare) (external link)

Back to the top of this page